DDInter1590 DDInter1628
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Rifampicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) interacts with {v} (Gene) NFKB1
NFKB1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) binds {v} (Gene) ABCC3
ABCC3 {u} (Gene) interacts with {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) regulates {v} (Gene) ITGB1BP1
ITGB1BP1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) covaries with {v} (Gene) ACADS
ACADS {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Rifampicin {u} (Compound) binds {v} (Gene) ABCC3
ABCC3 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Rifampicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Rifampicin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) interacts with NFKB1 (Gene) and NFKB1 (Gene) is upregulated by Ruxolitinib (Compound)
Rifampicin (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Rifampicin (Compound) binds ABCC3 (Gene) and ABCC3 (Gene) interacts with BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Ruxolitinib (Compound)
Rifampicin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) regulates ITGB1BP1 (Gene) and ITGB1BP1 (Gene) is downregulated by Ruxolitinib (Compound)
Rifampicin (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) covaries with ACADS (Gene) and ACADS (Gene) is downregulated by Ruxolitinib (Compound)
Rifampicin (Compound) binds ABCC3 (Gene) and ABCC3 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)